Newsdesk, Author at Market Newsdesk

November 13, 2020 11:00 am

ALYI Publishes $100 Million ICO Update From Finance Partner RevoltTOKEN

PR Newswire

DALLAS, Nov. 13, 2020 /PRNewswire/ — Alternet Systems, Inc. (USOTC: ALYI) today announced an update released from their financing partner, RevoltTOKEN. The update from RevoltTOKEN CEO, Henryk Dabrowski, is included below:

RevoltTOKEN ICO Update

The response to the RevoltTOKEN ICO has been tremendous. We are here at RevoltTOKEN are humbled by the number of people contacting us ready to purchase Tokens. We are also encouraged by the response and in reaction to the response, confident that RevoltTOKEN will meet or exceed its $100 million funding objectives.

We are making steady progress on the necessary preparations for the ICO. We are also trying to meet the eager market response by moving as quickly through the necessary preparations as possible.

We have previously announced that RevoltTOKEN is domiciling in Bermuda. Cryptocurrency is a relatively new financing tool. We have selected a sound technology platform, Ethereum, and we equally think it is important to prudently select a legal domain.

Bermuda is a globally respected business venue with a well-established and efficiently operating legal environment governing business transactions. Bermuda has elected to take a leadership role in facilitating a cryptocurrency business environment with a standard of integrity that supports investor confidence.

As eager as we are to quickly launch the ICO, are eagerness is balanced by our prudence in carefully insuring a sound regulatory approach into an environment with only a short history of rules and regulations.

We are confident our internal investment resources can satisfy ALYI’s intermediate requirements pending the ICO. If necessary, we are willing to increase our existing interim investment commitments.

In Bermuda’s defense, since we have engaged to domicile and register as a cryptocurrency, Bermuda, like everyone, has had to deal with the restrictions of operating in a COVID environment in addition to dealing with a hurricane coming ashore followed by another near miss. So, in addition to carefully managing a new financing tool, Bermuda is doing so in the face of some rather notable distractions.

In an effort to exercise the greatest prudence within the new cryptocurrency regulatory environment, RevoltTOKEN is currently exploring and intends to engage more than one registration venue. In addition to registering as a cryptocurrency in Bermuda, RevoltTOKEN intends to register in additional regulatory domains.

The public trading of stocks has 400 years of history to draw on for regulatory standards. Cryptocurrencies barely have a 10-year history since inception. We anticipate a set of universal regulatory standards for cryptocurrencies someday similar to the universal standard for stocks. At the moment, there is not much of a body of any rules and standards and different legal domains are developing different standards. Also, keep in mind, a larger number of cryptocurrencies trade today without being registered or licensed in any domain.

At RevoltTOKEN we think it is worthwhile to register in multiple domains in an effort to bridge the lack of a universal standard.

We look forward to the ultimate launch of the RevoltTOKEN ICO and working diligently to get there at the right time with the right amount of structure. We will continue to keep you posted on our progress.

For more information and to stay up to date on RevoltTOKEN’s latest developments, please visit www.revolttoken.com.

For more information and to stay up to date on ALYI’s latest developments, please visit www.alternetsystemsinc.com.

Disclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Alternet Systems, Inc. Contact:
Randell Torno
[email protected]
+1-800-713-0297

View original content:http://www.prnewswire.com/news-releases/alyi-publishes-100-million-ico-update-from-finance-partner-revolttoken-301172847.html

SOURCE Alternet Systems, Inc.

November 13, 2020 10:59 am

SunLink Health Systems, Inc. Announces Fiscal 2021 First Quarter Results and COVID-19 Update

SunLink Health Systems, Inc. Announces Fiscal 2021 First Quarter Results and COVID-19 Update

ATLANTA–(BUSINESS WIRE)–
SunLink Health Systems, Inc. (NYSE American: SSY) today announced a loss from continuing operations of $291,000 (a loss of $0.04 per fully diluted share) for its first fiscal quarter ended September 30, 2020 compared to a loss of $143,000, (a loss of $0.02 per fully diluted share) for the quarter ended September 30, 2019. Net loss for the quarter ended September 30, 2020 was $340,000 (a loss of $0.05 per fully diluted share) compared to a net loss of $261,000 ($0.04 per fully diluted share) for the quarter ended September 30, 2019.

Consolidated net revenues from continuing operations for the quarters ended September 30, 2020 and 2019 were $10,422,000 and $11,652,000, respectively, a decrease of 10.6% in the current fiscal year’s first quarter compared to the comparable quarter of the prior fiscal year. Net revenues decreased in the current fiscal quarter primarily due to decreased hospital and nursing home net revenues and decreased Pharmacy segment revenues as a result of decreased sales in all product categories primarily due to the COVID-19 pandemic.

SunLink reported an operating loss for the quarter ended September 30, 2020 of $323,000 compared to an operating loss for the quarter ended September 30, 2019 of $220,000.

Loss from discontinued operations was $49,000 (or a loss of $0.01 per fully diluted share) for the quarter ended September 30, 2020 compared to a loss from discontinued operations of $118,000 ($0.02 per fully diluted share) for the quarter ended September 30, 2019.

COVID-19 Pandemic

A novel strain of coronavirus (“COVID-19”) was declared a global pandemic by the World Health Organization on March 11, 2020. We have been monitoring the COVID-19 pandemic and its impact on our operations, and we have taken significant steps intended to minimize the risk to our employees and patients. Certain employees have been working remotely, but we believe these remote work arrangements have not materially affected our ability to maintain critical business operations, which are being conducted substantially in accordance with our understanding of applicable government health and safety protocols and guidance issued in response to the COVID-19 pandemic, although such protocols and guidance are very recent, rapidly changing and at times, unclear. Nevertheless, as in many healthcare environments, we have experienced COVID-19 illness, including deaths, and some employees have tested positive and were placed on leave or in quarantine.

In our Healthcare businesses, we have experienced material reductions in demand and net revenues due to the COVID-19 outbreak. There appears to be minimal current demand for nursing home admissions, and clinic visits and hospital services have substantially decreased as well in part due to the abrupt retirement of one physician and reduced capacity of other physicians and providers, all as a result of the effects of the pandemic. The availability and cost of medical supplies have adversely affected our Healthcare businesses, especially with respect to access to personal protective equipment, cleaning supplies and COVID-19 testing materials. We continue to monitor supplies and seek additional sources of many supply items. A reduction in the availability of qualified employees has also occurred and despite good faith efforts to do, we have not yet been able to rehire or fully replace staff reductions which were previously furloughed, laid off or retired.

Since the beginning of the COVID-19 pandemic, our Pharmacy business has experienced reduced sales trends in certain areas, increased costs and reduced staff. Many of our primary physician referral sources have been operating at substantially reduced capacity. Until these referral sources are at full capacity, we believe the COVID-19 pandemic will continue to affect the demand for DME products and Retail and Institutional Pharmacy drugs and products. Reductions in employee hours have been made in response to the lower demand. Nursing homes and other customers of such Institutional Pharmacy services are currently being adversely affected by the spreading of the COVID-19 pandemic, and this may be expected to have a further negative effect on such demand. Our Institutional Pharmacy services have experienced increased costs and operational inefficiencies due to measures taken to protect our employees and by access controls and other restrictions implemented by our institutional customers. The impact of the COVID-19 pandemic has negatively affected our supply processes, especially with respect to access to respiratory equipment and certain personal protective equipment and cleaning products. We believe the effect of the COVID–19 pandemic and public and governmental responses to it negatively affected our last three fiscal quarters results.

During the fourth quarter of fiscal 2020, our Healthcare and Pharmacy segments received approximately $4,586,000 and in the first quarter of fiscal 2021 we received $106,000 in general and targeted Provider Relief Fund (“PRF”) distributions. During the fourth quarter of fiscal 2020, we also received $3,234,000 in Paycheck Protection Program (“PPP”) loans, administered by the Small Business Administration (“SBA”). Both the PRF and PPP funds are provided for under the Coronavirus Aid Relief and Economic Security (“CARES”) Act, and we have received a total of $7,926,000 of such funding.

The distributions from the PRF are not subject to repayment provided we are able to attest to and comply with the terms and conditions of the funding, including demonstrating that the funds received have been used for healthcare-related expenses or “Lost Revenues” (as defined by HHS) attributable to COVID-19. Such funds under the PRF are accounted for as government grants and are recognized on a systematic and rational basis once there is reasonable assurance that the applicable terms and conditions required to retain the funds have been met. HHS has released “CARES Act Provider Relief Fund Frequently Asked Questions” (“FAQ”) numerous times since April 3, 2020 through October 28, 2020 to clarify PRF requirements and has provided expansive examples of the reporting requirements in efforts to demonstrate what amounts of the PRF received may be considered to have been earned and may be retained. The Company continues to review and analyze the FAQ which it believes still leaves substantial uncertainty as to the proper use and reporting of PRF funds. We are reporting $31 of PRF in other income in our consolidated statement of operations for our fiscal quarter ended September 30, 2020 for COVID-19 related expenses. The unrecognized amount of the PRF are recorded under the caption “Unearned CARES Act Funds” in our consolidated balance sheets. We will continue to monitor compliance with the terms and conditions of the PRF and the impact of the pandemic on our revenues and expenses. If we are unable to attest to or comply with current or future terms and conditions, and there is no assurance we will be able to do so, our ability to retain some or all of the distributions received may be impacted. We currently believe we may not be able to utilize a portion of the PRF funds received under the currently existing interpretations by HHS and have to return the unutilized funds in the future.

Forgiveness of PPP loans may be available if the loans are used to pay wages, rent, utilities and interest on certain debt during the eight-week period following receipt of the loan proceeds, subject to Federally-established terms and conditions. During July 2020, the allowable period for the use of PPP loan proceeds was amended to allow for a 24-week utilization period. The borrowing subsidiaries must apply for loan forgiveness with the lending bank within ten months after the end of the allowable period. The forgiveness applications are to be reviewed by both the lender and the SBA and a loan forgiveness amount, if any, will be determined. There can be no assurance, however, that any of the PPP loans to us will be forgiven, or if forgiven, the amount of such forgiveness. Loan proceeds not forgiven are payable over two years at a 1% annual interest rate. The two-year loan repayment begins two months after the loan forgiveness amount is determined by SBA. The Company has not yet applied for forgiveness of any of its PPP loans and recorded no income relating to the PPP loans through September 30, 2020.

Going forward, the Company is unable to determine the extent to which the COVID-19 pandemic will continue to affect its assets and operations. Our ability to make estimates of the effect of the COVID-19 pandemic on revenues, expenses or changes in accounting judgments that have had or are reasonably likely to have a material effect on our financial statements is currently limited. The nature and extent of the effect of the COVID-19 pandemic on our balance sheet and results of operations will depend on the severity and length of the pandemic; government actions to mitigate the pandemic’s effect; regulatory changes in response to the pandemic, especially those that affect our hospital, nursing home and pharmacy operations; and existing and potential government assistance that may be provided, including the requirements applicable to PRF receipts and PPP loans.

SunLink Health Systems, Inc. is the parent company of subsidiaries that own and operate healthcare properties and businesses in the Southeast. Each of the Company’s businesses is operated locally with a strategy of linking patients’ needs with healthcare professionals. For additional information on SunLink Health Systems, Inc., please visit the Company’s website.

This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 including, without limitation, statements regarding the company’s business strategy. These forward-looking statements are subject to certain risks, uncertainties and other factors, which could cause actual results, performance and achievements to differ materially from those anticipated. Certain of those risks, uncertainties and other factors are disclosed in more detail in the company’s Annual Report on Form 10-K for the year ended June 30, 2020 and other filings with the Securities and Exchange Commission which can be located at www.sec.gov.


SUNLINK HEALTH SYSTEMS, INC. ANNOUNCES
FISCAL 2021 FIRST QUARTER RESULTS
Amounts in 000’s, except per share and volume amounts

CONSOLIDATED STATEMENTS OF EARNINGS (LOSS)
	Three Months Ended September 30,
		2020						2019
					% of Net						% of Net
		Amount			Revenues			Amount			Revenues
Net Revenues		$	10,422			100.0	%	$	11,652		100.0	%
Costs and Expenses:
Cost of goods sold			4,070			39.1	%		4,344		37.3	%
Salaries, wages and benefits			4,385			42.1	%		4,909		42.1	%
Supplies			224			2.1	%		319		2.7	%
Purchased services			647			6.2	%		703		6.0	%
Other operating expenses			949			9.1	%		1,103		9.5	%
Rents and leases			170			1.6	%		159		1.4	%
Depreciation and amortization			300			2.9	%		335		2.9	%
Operating Loss			(323	)		-3.1	%		(220	)	-1.9	%

Interest Expense – net			(7	)		-0.1	%		(30	)	-0.3	%
Federal stimulus – Pandemic relief funds			31			0.3	%		0		0.0	%
Gains on sale of assets			8			0.1	%		107		0.9	%

Loss from Continuing Operations before
Income Taxes			(291	)		-2.8	%		(143	)	-1.2	%
Income Tax expense (benefit)			0			0.0	%		0		0.0	%
Loss from Continuing Operations			(291	)		-2.8	%		(143	)	-1.2	%
Earnings (Loss) from Discontinued Operations, net of tax			(49	)		-0.5	%		(118	)	-1.0	%
Net Loss		$	(340	)		-3.3	%	$	(261	)	-2.2	%
Loss Per Share from Continuing Operations:
Basic		$	(0.04	)				$	(0.02	)
Diluted		$	(0.04	)				$	(0.02	)
Earnings (Loss) Per Share from Discontinued Operations:
Basic		$	(0.01	)				$	(0.02	)
Diluted		$	(0.01	)				$	(0.02	)
Net Loss Per Share:
Basic		$	(0.05	)				$	(0.04	)
Diluted		$	(0.05	)				$	(0.04	)
Weighted Average Common Shares Outstanding:
Basic			6,899						6,987
Diluted			6,899						6,987

HEALTHCARE FACILITIES VOLUME STATISTICS

Hospital and Nursing Home Admissions			66						122
Hospital and Nursing Home Patient Days			5,195						6,961

SUMMARY BALANCE SHEETS		September 30,			June 30,
			2020			2020
ASSETS
Cash and Cash Equivalents		$	11,403		$	11,184
Accounts Receivable – net			4,195			4,315
Other Current Assets			4,420			4,424
Property Plant and Equipment, net			5,622			5,324
Long-term Assets			2,605			2,724
		$	28,245		$	27,971
LIABILITIES AND SHAREHOLDERS’ EQUITY
Accounts Payable		$	1,614		$	872
Unearned CARES Act Funds			4,607			4,532
Other Current Liabilities			5,867			6,012
Long-term Debt and Other Noncurrent Liabilities			2,754			2,812
Shareholders’ Equity			13,403			13,743
		$	28,245		$	27,971

View source version on businesswire.com: https://www.businesswire.com/news/home/20201113005530/en/

Robert M. Thornton, Jr.

Chief Executive Officer

(770) 933-7004

KEYWORDS: Georgia United States North America

INDUSTRY KEYWORDS: Hospitals Health Pharmaceutical Nursing Medical Supplies

MEDIA:

Logo

November 13, 2020 10:55 am

PCS Edventures! Reports Unaudited Results for the Second Quarter of Fiscal Year 2021

BOISE, Idaho, Nov. 13, 2020 (GLOBE NEWSWIRE) — PCS Edventures!, Inc., (PCSV) a leading provider of K-12 Science, Technology, Engineering and Mathematics (STEM) education programs and drone products, today announced unaudited results of operations for its second quarter of Fiscal Year 2021 which ended on September 30, 2020.

Revenue was $0.39 million, which was down 54% from the revenue generated in the same period last year. Net income was ($0.21 million) compared to $0.58 million for the same period last year.

Michael Bledsoe, President, commented, “While schools are starting to cautiously go back to in-person learning, the classroom environment has changed. In more instances than not, school supplies and enrichment materials are no longer shared, sometimes by state mandate, with the intention of reducing the risk of COVID-19 transmission. This has presented a challenge for us, as many of our STEM products and curriculum include group activities designed to develop critical communication skills required in team environments. We continue to work with educators from all over the country to understand their needs and how we can best satisfy them.”

Mr. Bledsoe continued, “In response to our new environment, we have developed a program called BrickLABSTEAMventures to serve remote and social-distancing environments. Students use their own individualized set of bricks to engage in hands-on learning guided by STEAMventures activity books. The bricks are an initial purchase that can be reused with each new issue. We have also individualized some of our enrichment programs and are working with educators to determine the best way to teach the educational content of the program while staying in compliance with school safety guidelines. We recognize the potential to market individualized kits and programs to retail consumers, especially given the increase in the home-schooling population, and we are working to address these new markets and opportunities. We are encouraged by early results of all of these efforts.”

For more information about PCS Edventures!, Inc., visit our website.

Company financial information and reports can be found at https://www.otcmarkets.com/.

About PCS
Edventures
!, Inc.

PCS Edventures!, Inc. (OTCPK: PCSV) is a Boise, Idaho company that designs and delivers technology-rich products and services for the K-12 market that develop 21st-century skills. PCS programs emphasize experiential learning in Science, Technology, Engineering, and Math (STEM). https://www.edventures.com/.

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934; actual results could differ materially from such statements.

Contact

Investor Contact: Michael Bledsoe 1.800.429.3110, [email protected]
Investor Relations Web Site: pcsv.global

November 13, 2020 10:53 am

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Biogen Inc. – BIIB

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Biogen Inc. – BIIB

NEW YORK–(BUSINESS WIRE)–
Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Biogen Inc. (NASDAQ: BIIB), between October 22, 2019 and November 6, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Biogen investors under the federal securities laws.

To join the Biogen class action, go to http://www.rosenlegal.com/cases-register-1981.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the larger dataset did not provide necessary data regarding aducanumab’s effectiveness; (2) the EMERGE study did not and would not provide necessary data regarding aducanumab’s effectiveness; (3) the PRIME study did not and would not provide necessary data regarding aducanumab’s effectiveness; (4) the data provided by the Company to the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee did not support finding efficacy of aducanumab; and (5) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 12, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1981.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201113005523/en/

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.

275 Madison Avenue, 40^th Floor

New York, NY 10016

Tel: (212) 686-1060

Toll Free: (866) 767-3653

Fax: (212) 202-3827

[email protected]

[email protected]

[email protected]
www.rosenlegal.com

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

November 13, 2020 10:52 am

BUSH’S® Beans Joins Chili Championship to Myrtle Beach

MYRTLE BEACH, S.C., Nov. 13, 2020 (GLOBE NEWSWIRE) — To bean, or not to bean. That is no longer a question at the World Championship Chili Cook-Off (WCCC), which will be held April 9-11, 2021, for the first time in Myrtle Beach, South Carolina.

The International Chili Society (ICS), the sanctioning body for the WCCC, announced today that it will be featuring BUSH’S® Beans as the presenting sponsor of the iconic cookoff.

“BUSH’S® Beans is a wonderful company with a great history, just like the World Championship Chili Cook-off,” commented Mike McCloud, the CEO of ICS. “For more than 50 years, our championship has delighted chili heads around the world with our Traditional Red and Verde categories of chili. And this year, our Homestyle division will be just as impressive as we welcome BUSH’S® to the table and invite chili cooks of all ages, including children, to Myrtle Beach for an incredible chili beach bash.”

For more than 100 years, chili fans seeking unparalleled flavor and quality have reached for BUSH’S. The brand’s Chili Beans, which are known for a special blend of chilies, spices, garlic and onions, will be on hand this year to help contestants make their best chili even better.

“BUSH’S is thrilled to sponsor the 2021 World Championship Chili Cookoffs,” said Brittanie Weaver, Bush’s Director of Marketing. “Our slow-simmered and perfectly seasoned Chili Beans have played a long standing role in different types of chili-inspired dishes, so we are excited to help show uninitiated chili-heads why BUSH’S Chili Beans are the Chili Beans of the pros.”

Almost $100,000 will be up for grabs at the 54th WCCC, which was started by legendary automotive enthusiast Carroll Shelby and friends. The 2021 categories include Traditional Red, Homestyle, Chili Verde, Veggie, and the much-anticipated return of Salsa. A “Last Chance” category will also be available to competitors who did not get the chance to qualify due to cook-off cancellations and an unprecedented year. Additionally, WCCC will host a “Corporate Cup Challenge” for local businesses in the Myrtle Beach Area that want to try their turn at Chili competition. To learn more information about the event, simply follow the World Championship Chili Cook Off on Facebook, Twitter and Instagram.

About the International Chili Society

Since 1967, the International Chili Society (ICS) has been bringing people together over one of America’s greatest culinary creations. ICS sanctions more than 100 events a year nationwide with one mission – to continuously improve chili while raising money for charities and nonprofits. More than $100 million has been raised for charities by the chili arena since ICS was started. To celebrate each year’s pro-chili season, ICS holds a World Chili Championship Cookoff (WCCC) and crowns World Champions. To see previous winners, click here.

About BUSH’S® Beans

Family-owned since 1908, BUSH’S® is all about friends & family, and a certain Secret Family Recipe. When you enjoy BUSH’S Beans (doesn’t matter if they’re Baked Beans, chili beans, black beans, pinto beans…well, you get the picture), you can trust that they’re the very best. Because BUSH’S wouldn’t serve your family anything less. Since their start more than 110 years ago in Chestnut Hill, Tennessee, BUSH’S has always maintained that quality is the best policy. They pursue excellence and exceptional taste in their beans, sauces and everything we do. That’s why, from mouthwatering Baked Beans & Chili Beans to satisfying bean recipes, you’re cooking up the best with BUSH’S BEST®. For more information, visit www.bushbeans.com.

Attachment

2020-11-13

Alli Sparks
International Chili Society
[email protected]

November 13, 2020 10:48 am

Should you invest in Applied Materials, Xpeng Inc, Ross Stores, Apple, or American Airlines?

PR Newswire

NEW YORK, Nov. 13, 2020 /PRNewswire/ — InvestorsObserver issues critical PriceWatch Alerts for AMAT, XPEV, ROST, AAPL, and AAL.

Click a link below then choose between in-depth options trade idea report or a stock score report.

Options Report – Ideal trade ideas on up to seven different options trading strategies. The report shows all vital aspects of each option trade idea for each stock.

Stock Report – Measures a stock’s suitability for investment with a proprietary scoring system combining short and long-term technical factors with Wall Street’s opinion including a 12-month price forecast.

(Note: You may have to copy this link into your browser then press the [ENTER] key.)

View original content to download multimedia:http://www.prnewswire.com/news-releases/should-you-invest-in-applied-materials-xpeng-inc-ross-stores-apple-or-american-airlines-301172826.html

SOURCE InvestorsObserver

November 13, 2020 10:48 am

Thinking about buying stock in Electrameccanica Vehicles, Moneygram International, GrowGeneration, Nokia, or Fisker?

PR Newswire

NEW YORK, Nov. 13, 2020 /PRNewswire/ — InvestorsObserver issues critical PriceWatch Alerts for SOLO, MGI, GRWG, NOK, and FSR.

To see how InvestorsObserver’s proprietary scoring system rates these stocks, view the InvestorsObserver’s PriceWatch Alert by selecting the corresponding link.

(Note: You may have to copy this link into your browser then press the [ENTER] key.)

InvestorsObserver’s PriceWatch Alerts are based on our proprietary scoring methodology. Each stock is evaluated based on short-term technical, long-term technical and fundamental factors. Each of those scores is then combined into an overall score that determines a stock’s overall suitability for investment.

View original content to download multimedia:http://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-electrameccanica-vehicles-moneygram-international-growgeneration-nokia-or-fisker-301172829.html

SOURCE InvestorsObserver

November 13, 2020 10:48 am

ROSEN, A TOP RANKED LAW FIRM, Announces Investigation of Securities Claims Against MultiPlan Corporation; Encourages Investors with Losses in Excess of $100K to Contact Firm – MPLN

PR Newswire

NEW YORK, Nov. 13, 2020 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of MultiPlan Corporation (NYSE: MPLN) resulting from allegations that MultiPlan may have issued materially misleading business information to the investing public.

On November 11, 2020, Muddy Waters Research published a report entitled “MultiPlan: Private Equity Necrophilia Meets The Great 2020 Money Grab[.]” The Muddy Waters report described a series of issues involving MultiPlan including that “MPLN is in the process of losing its largest client, UnitedHealthcare (‘UHC’). UHC has formed a competitor to MPLN that offers significantly lower prices and fewer conflicts of interest.”

On this news, MultiPlan’s stock price fell $2.46 per share, or 28%, over the next two trading days to close at $6.27 per share on November 12, 2020.

Rosen Law Firm is preparing a securities lawsuit on behalf of MultiPlan shareholders. If you purchased securities of MultiPlan please visit the firm’s website at http://www.rosenlegal.com/cases-register-1983.html to join the securities action. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40^th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      [email protected]
      [email protected]
      www.rosenlegal.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/rosen-a-top-ranked-law-firm-announces-investigation-of-securities-claims-against-multiplan-corporation-encourages-investors-with-losses-in-excess-of-100k-to-contact-firm–mpln-301172833.html

SOURCE Rosen Law Firm, P.A.

November 13, 2020 10:45 am

Sun Life awards grants to local organizations across the country to support community diabetes programs

PR Newswire

WELLESLEY, Mass., Nov. 13, 2020 /PRNewswire/ — In recognition of World Diabetes Day on November 14, Sun Life has announced the winners of the annual Team Up Against Diabetes grant program. Every year Sun Life U.S. supports five grassroots organizations that administer diabetes support, management, education and awareness programs in high-risk or underserved communities. This year’s recipients support minority communities who, as studies have shown, often have reduced access to healthcare and health support, and are disproportionately vulnerable to diabetes and its complications.

“Sun Life has an important role to play in helping our communities feel supported and safe, especially at a difficult time like this when health is at risk,” said Dan Fishbein, M.D., president of Sun Life U.S. “Our support will help these organizations continue the great work they are doing to address the needs of those with diabetes and pre-diabetes, while also addressing important topics around health disparities and food insecurity – both of which have been exacerbated by COVID-19.”

2020 Sun Life Team Up Against Diabetes grant program winners:

Emory University, Leveraging Soccer to Prevent Diabetes Among Minority Men, Atlanta
Emory has implemented a soccer-based Diabetes Prevention Program to engage minority men with the goal of reversing a prediabetes diagnosis. Trained soccer coaches will lead facilitated discussions using the U.S. Centers for Disease Control National Diabetes Prevention Program modules, along with rigorous game play that incorporates a fitness curriculum from FIFA and other resources. The goal is for participants to reverse their prediabetes, as well as demonstrate sustained weight-loss and exhibit new knowledge of exercise, nutrition and wellness. Sun Life’s support will cover all costs for program participants.

Hunger Intervention Program, Community Food and Fitness Program, Seattle
Hunger Intervention Program’s (HIP) mission is to increase food security for underserved populations through nutritious meals, prevention education programs and anti-hunger advocacy. HIP’s Community Food and Fitness Program seeks to improve health in Latinx, Southeast Asian and African American communities through culturally relevant nutrition education, cooking classes, fitness activities, and health-related workshops, centered around a communal meal event. Sun Life’s grant support will allow HIP to hold these events more frequently, with expanded access to cooking and nutrition education for children as well.

Physicians Committee for Responsible Medicine, Native Food for Life, Washington, D.C.
The Native Food for Life program focuses on the prevention and reversal of diabetes in the Navajo Nation and the Eight Northern Pueblos of New Mexico. American Indian and Alaskan Native populations shoulder a disproportionate burden of type 2 diabetes among adults, according to the CDC. The program’s diabetes prevention, treatment, and reversal curriculum uses ancestral wisdom and Navajo culture to help restore participants’ physical health and vitality over the course of a 12-week period. Sun Life’s grant support will allow for an online adaptation of the curriculum, will train local experts to assist in program delivery, and will help launch community workshops in four new locations. In moving their materials to an online format, coupled with the additional community workshops, the program will reach over 10,000 individuals in the Navajo Nation.

Supportive Older Women’s Network, Philly Families Eat Smart, Philadelphia
Supportive Older Women’s Network provides innovative solutions to 50+ adults so they can lead healthy, independent lives and age in place within their homes and communities. Sun Life’s grant will support Philly Families Eat Smart (PFES), which focuses on healthy eating and physical activity in grandparent-led families. The majority of grandparents supported by the program are African-American women over 60 who live in impoverished areas and cope with chronic health conditions like diabetes, which limit their daily activities. PFES covers nutrition, healthy cooking, and culturally appropriate diets, and aims to improve health behavior with creative solutions to help ensure lifestyle changes are permanent.

Victory Programs, ReVision Urban Farm, Boston
The ReVision Urban Farm program provides food insecure families in the Dorchester and Mattapan areas of Boston with fresh produce and nutrition education. The Farm aims to reduce health disparities for low-income families, educate on the benefits of healthy eating and build coalitions to advance community health. Sun Life’s support will expand the reach of food security to the program’s ReVision Family Home for homeless families, and other area residents in need. The grant will also increase levels of nutrition education and healthy cooking skills, as well as help Victory Programs build a coalition with local health centers and community groups to help close the health disparity gap in the Boston area.

“The pandemic has put a spotlight on health inequality in this country, and we must be active participants in the solution,” added Fishbein. “We are proud to support these incredible organizations that are providing such important community services.”

The Sun Life Team Up Against Diabetes grant program is in its fifth year and has distributed $1 million to diabetes programs across the country. It is part of Sun Life’s broader efforts to address diabetes and equal access to healthcare, which include community parnerships with the Boston Celtics and Kansas City Royals.

For more information about the Team Up Against Diabetes grant progam, visit www.sunlife.com/usgrants.

About Sun Life
Sun Life is a leading international financial services organization providing insurance, wealth and asset management solutions to individual and corporate Clients. Sun Life has operations in a number of markets worldwide, including Canada, the United States, the United Kingdom, Ireland, Hong Kong, the Philippines, Japan, Indonesia, India, China, Australia, Singapore, Vietnam, Malaysia and Bermuda. As of September 30, 2020, Sun Life had total assets under management of C$1,186 billion. For more information, please visit www.sunlife.com.

Sun Life Financial Inc. trades on the Toronto (TSX), New York (NYSE) and Philippine (PSE) stock exchanges under the ticker symbol SLF.

In the United States, Sun Life is one of the largest group benefits providers, serving more than 60,000 employers in small, medium and large workplaces across the country. Sun Life’s broad portfolio of insurance products and services in the U.S. includes disability, absence management, life, dental, vision, voluntary and medical stop-loss. Sun Life and its affiliates in asset management businesses in the U.S. employ approximately 5,500 people. Group insurance policies are issued by Sun Life Assurance Company of Canada (Wellesley Hills, Mass.), except in New York, where policies are issued by Sun Life and Health Insurance Company (U.S.) (Lansing, Mich.). For more information, please visit www.sunlife.com/us.

Media contact:

Devon Fernald

Sun Life U.S.
781-800-3609
[email protected]

Connect with Sun Life U.S.

https://www.facebook.com/SLFUnitedStates

https://www.linkedin.com/company/sun-life-financial

https://twitter.com/SunLifeUS

View original content to download multimedia:http://www.prnewswire.com/news-releases/sun-life-awards-grants-to-local-organizations-across-the-country-to-support-community-diabetes-programs-301172837.html

SOURCE Sun Life U.S.

November 13, 2020 10:43 am

Apellis Announces Late-Breaking Presentation of Largest Retrospective Database Study in Geographic Atrophy (GA) at AAO 2020 Virtual

Verana Health a
nalysis of American Academy of Ophthalmology IRIS
^®
Registry presented in a late-breaking oral session
Real-world clinical data show significant disease progression over a two-year period in more than 69,000 patients with GA, highlighting the urgent need for treatment
Patients were nearly three times more likely to develop
new onset
wet
age-related macular degeneration
(
AMD
)
in an eye with GA when wet AMD had already been detected in the
contralateral
eye

WALTHAM, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced findings from the largest retrospective database study in geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The analysis of the American Academy of Ophthalmology (AAO) IRIS^® (Intelligent Research in Sight) Registry, the nation’s first comprehensive clinical registry for eye disease, was conducted in partnership with Verana Health, the world’s leading data analysis group in retinal diseases. The study highlights the significant impact of GA progression on vision, underscoring the high unmet need for GA treatment in clinical practice. The data were presented today in a late-breaking oral session as part of the Retina Subspecialty Day at AAO 2020 Virtual.

The retrospective study included more than 69,000 patients diagnosed with GA and analyzed changes in visual acuity and disease progression for over two years, as well as the occurrence of concurrent wet AMD. GA is a complement-driven eye disease^1,2 that can lead to significant vision loss and affects approximately five million people around the world.^3,4 

“There is no approved therapy for GA and with new agents under development, it is essential to have a detailed understanding of disease progression in real-world clinical practice,” said Ehsan Rahimy, M.D., lead study author and surgical and medical vitreoretinal specialist at the Palo Alto Medical Foundation. “The data show that GA patients at their first encounter have useful vision that may be preserved if an effective treatment were available. The progressive loss of visual acuity observed in this study over a two-year period underscores the urgent need for a therapy to slow disease progression.”

Key findings from the real-world clinical data show:

Progression from GA to new onset wet AMD was observed in 4.7% of patients with bilateral GA (GA in both eyes) and 13.3% of patients with wet AMD in the contralateral eye during the first 12 months. The rate at 24 months was 8.2% and 21.6% in bilateral GA and wet AMD in the contralateral eye, respectively.
At the first study visit, patients presented with relatively preserved vision, especially in eyes with extrafoveal GA lesions (lesions outside the fovea, which is the central portion of the retina). However, patients with extrafoveal and foveal GA lesions progressively lost vision over time at a rate of approximately five letters per year.
A large proportion of GA patients did not return for a follow-up visit after two years. Of the GA patients potentially eligible for inclusion in the analysis, only 40% had a follow-up visit after two years and were ultimately included in the study.

“As we work to develop the first potential medicine for people with GA, we are committed to improving understanding of the disease. Our collaboration with Verana Health and the AAO IRIS^® Registry shows that wet AMD is not a rare occurrence in GA patients, and there is an opportunity to preserve vision if new treatments become available,” said Federico Grossi, M.D., Ph.D., chief medical officer of Apellis. “These results highlight the significant unmet need in GA, and we are working urgently to advance pegcetacoplan, a targeted C3 therapy, in two ongoing Phase 3 GA studies.”

About the IRIS
^®
Registry

The American Academy of Ophthalmology IRIS^® (Intelligent Research in Sight) Registry is the nation’s first electronic health record-based comprehensive eye disease and condition registry. As of September 2020, the registry features over 59.99 million unique patients and includes 16,030 clinicians. It is a centralized data repository and reporting tool that can analyze patient data to produce easy-to-interpret national and inter-practice benchmark reports and provide scientific information to improve public health. The reports can validate the quality of care ophthalmologists provide and pinpoint opportunities for improvement.

About Verana Health

Verana Health, Inc. partners with leading medical associations to transform clinical data into actionable real-world evidence. These partnerships enable Verana Health to harness the comprehensive data found in qualified clinical data registries and other specialty data sources to accelerate medical research and enhance patient care. Learn more at veranahealth.com.

About Geographic Atrophy (GA) 
GA is an advanced form of age-related macular degeneration (AMD), a leading cause of blindness. Excessive complement activation drives irreversible lesion growth in GA,⁵ and C3 is the only target to precisely control complement overactivation. Pegcetacoplan, studied in early and late-stage trials comprising a total of approximately 1,500 patients, is the only targeted C3 inhibitor being evaluated in late-stage trials to control lesion growth in GA.⁶

GA lesions affect the central portion of the retina, known as the macula, which is responsible for central vision. GA is progressive and irreversible, leading to central visual impairment and permanent loss of vision. Based on published studies, approximately one million people have GA in the United States and five million people have GA globally.^2,7 There are currently no approved treatments for GA.

About Pegcetacoplan (APL-2) 
Pegcetacoplan is an investigational, targeted C3 therapy designed to regulate excessive activation of the complement cascade, part of the body’s immune system, which can lead to the onset and progression of many serious diseases. Pegcetacoplan is a synthetic cyclic peptide conjugated to a polyethylene glycol polymer that binds specifically to C3 and C3b. Apellis is evaluating pegcetacoplan in several clinical studies across hematology, ophthalmology, nephrology, and neurology. Pegcetacoplan was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and the treatment of geographic atrophy, and received orphan drug designation for the treatment of C3 glomerulopathy (C3G) by the FDA and European Medicines Agency. For additional information regarding our clinical trials, visit https://apellis.com/our-science/clinical-trials.

About Apellis 
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, we aim to develop transformative therapies for a broad range of debilitating diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology. For more information, please visit http://apellis.com.

Apellis Forward-Looking Statement
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the implications of preliminary clinical data. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether the company’s clinical trials will be fully enrolled and completed when anticipated; whether preliminary or interim results from a clinical trial will be predictive of the final results of the trial; whether results obtained in preclinical studies and clinical trials will be indicative of results that will be generated in future clinical trials; whether pegcetacoplan will successfully advance through the clinical trial process on a timely basis, or at all; whether the results of the company’s clinical trials will warrant regulatory submissions and whether pegcetacoplan will receive approval from the FDA or equivalent foreign regulatory agencies for GA, PNH, CAD, C3G, IC-MPGN, ALS or any other indication when expected or at all; whether, if Apellis’ products receive approval, they will be successfully distributed and marketed; and other factors discussed in the “Risk Factors” section of Apellis’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 2, 2020 and the risks described in other filings that Apellis may make with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Apellis specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. 

Media Contact:
Mark Dole
[email protected]
+1 617 997 3484

Investor Contact:
Argot Partners
[email protected]
+1 212 600 1902

¹Weber, BHF, Issa, PC, et al. The Role of the Complement System in Age-Related Macular Degeneration.
Dtsch Arztebl Int 2014; 111(8): 133–8.
² Heesterbeek, TJ, Lechanteur YTE, et al. Complement activation levels are related to disease stage in AMD. Invest Ophthalmol Vis Sci. 2020;61(3):18.
³ Rudnicka AR, Jarrar Z, Wormald R, et al. Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis. Ophthalmology 2012;119:571–580.
⁴ Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2014;2:e106–116.
⁵ Seddon, JM, Rosner, B. Validated prediction models for macular degeneration progression and predictors of visual acuity loss identify high-risk individuals. Am J Ophthalmol 2019;198:223–261. 
⁶ Yates, JRW, Sepp T, et al. Complement C3 Variant and the Risk of Age-Related Macular Degeneration. N Engl J Med 2007; 357.
⁷ Weber, BHF, Issa, PC, et al. The Role of the Complement System in Age-Related Macular Degeneration. Dtsch Arztebl Int 2014; 111(8): 133–8. 